Abstract: The clinical data of patients with severe adverse drug reactions in our hospital from January 1, 2018 to December 31, 2021 were analyzed to summarize the clinical characteristics, treatment and regression of severe adverse drug reactions.  A total of 65 patients including 15 of DRESS, 12 of TEN, 7 of SJS, 23 of AGEP and 8 of ED  were analyzed. The mean age of was 48.2±16.8 years, with a male to female ratio of 0.38∶1. The mean incubation period from the application of allergenic drugs to the onset of disease was 13.5±14.4 days. The allergenic drugs were mainly anti-infective drugs (30.7%) and proprietary Chinese medicines (20.0%). The liver function impairment was the most common concomitant symptom. Patients were divided into five groups:  31 patients in group 1 were treated with the conventional regimen of glucocorticoids alone. 11 patients in group 2 were given glucocorticoids combined with TNF-α antagonists due to poor efficacy of glucocorticoids alone or intolerance of hormonal side effects. 9 patients in group 3 who had rapid progression and severe symptoms were treated with glucocorticoids combined with TNF-α antagonists and intravenous immunoglobulin. 14 patients with relatively mild manifestation were treated with TNF-α antagonist （7 patients）or cyclosporine alone (7 patients). The average duration of skin lesion control for all patients was 8.8±3.0 days and the average length of stay was 16.8±4.4 days. The mean time to lesion control (7.4±1.3 days) and mean hospital stay (15.6±2.6 days) were lower in group 3 than in group 2 (9.5±2.6 days) and (18.1±5.5 days) (P<0.05). Follow-up 6 months after discharge, 58 patients cured and, the average duration of medication was 64.7±53.7 days, 3 cases received another hospitalization for recurrence, 2 died, 2 loss to follow-up.

Key words: severe adverse drug reactions, glucocorticoids, tumour necrosis factor antagonists, intravenous immunoglobulin